Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in the UK.
This review outlines the oral treatment options available for treating skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus (MRSA) in the community and discusses the evidence supporting their use.
Enoch
D A
DA
Clinical Microbiology & Public Health Laboratory, Peterborough District Hospital, Thorpe Road, Peterborough PE36JW, UK. david.enoch@pbh-tr.nhs.uk
Karas
J A
JA
Aliyu
S H
SH
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000382:microbiology*; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D006113:United Kingdom
D000900:Anti-Bacterial Agents